Cost-effectiveness of programmed cell death ligand 1 testing and tumor mutational burden testing of immune checkpoint inhibitors for advanced non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Li WQ 

PROVIDER: S-EPMC7722558 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature